Cargando…

PIG3 promotes NSCLC cell mitotic progression and is associated with poor prognosis of NSCLC patients

BACKGROUND: Non-small cell lung cancer (NSCLC) is the most commonly diagnosed type of lung cancer that is associated with poor prognosis. In this study we explored the potential role of p53-induced gene 3 (PIG3) in the progression of NSCLC. METHODS: Immunohistochemistry was used to determine the exp...

Descripción completa

Detalles Bibliográficos
Autores principales:	Li, Ming, Li, Shanhu, Liu, Biao, Gu, Meng-Meng, Zou, Shitao, Xiao, Bei-Bei, Yu, Lan, Ding, Wei-Qun, Zhou, Ping-Kun, Zhou, Jundong, Shang, Zeng-Fu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2017
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5336678/ https://www.ncbi.nlm.nih.gov/pubmed/28259183 http://dx.doi.org/10.1186/s13046-017-0508-2

Ejemplares similares

CLEC4M is associated with poor prognosis and promotes cisplatin resistance in NSCLC patients
por: Tan, Li-Ming, et al.
Publicado: (2019)

HDAC10 Is Positively Associated With PD-L1 Expression and Poor Prognosis in Patients With NSCLC
por: Liu, Xiaomei, et al.
Publicado: (2020)

Th1(high) in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC
por: Jian, Huang, et al.
Publicado: (2017)

Correction: Th1(high) in tumor microenvironment is an indicator of poor prognosis for patients with NSCLC
por: Jian, Huang, et al.
Publicado: (2017)

Decreased Preoperative Estimated Glomerular Filtration Rate Was Related With Poor Prognosis of NSCLC Patients
por: Jia, Wenqiao, et al.
Publicado: (2020)

Metastasis Patterns and Prognosis of Octogenarians with NSCLC: A Population-based Study
por: Gu, Yu, et al.
Publicado: (2020)

Ratiometric electrochemical OR gate assay for NSCLC-derived exosomes
por: Meng, Fanyu, et al.
Publicado: (2023)

DNA polymerase iota (Pol ι) promotes invasion and metastasis of esophageal squamous cell carcinoma
por: Zou, Shitao, et al.
Publicado: (2016)

Upregulation of ADAMDEC1 correlates with tumor progression and predicts poor prognosis in non‐small cell lung cancer (NSCLC) via the PI3K/AKT pathway
por: Zhu, Weiliang, et al.
Publicado: (2022)

Regional emphysema score is associated with tumor location and poor prognosis in completely resected NSCLC patients
por: Heo, Jung Won, et al.
Publicado: (2020)

Poor prognosis of NSCLC located in lower lobe is partly mediated by lower frequency of EGFR mutations
por: Lee, Hyun Woo, et al.
Publicado: (2020)

CIAPIN1 Targeted NHE1 and ERK1/2 to Suppress NSCLC Cells' Metastasis and Predicted Good Prognosis in NSCLC Patients Receiving Pulmonectomy
por: Wang, Jian, et al.
Publicado: (2019)

Sequence-Dependent Antiproliferative Effects of Gefitinib and Docetaxel on Non-Small Cell Lung Cancer (NSCLC) Cells and the Possible Mechanism
por: Chen, Bei, et al.
Publicado: (2014)

Elevated expression of FABP3 and FABP4 cooperatively correlates with poor prognosis in non-small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2016)

Effect of PFKFB4 on the Prognosis and Immune Regulation of NSCLC and Its Mechanism
por: Zhou, Yong, et al.
Publicado: (2022)

OPN Polymorphism Is Related to the Chemotherapy Response and Prognosis in Advanced NSCLC
por: Hao, Yanzhang, et al.
Publicado: (2014)

KRAS mutation is a weak, but valid predictor for poor prognosis and treatment outcomes in NSCLC: A meta-analysis of 41 studies
por: Pan, Wei, et al.
Publicado: (2016)

Clinicopathological and prognostic significance of Twist overexpression in NSCLC
por: Li, Meng, et al.
Publicado: (2018)

Metachronous Brain Metastasis in patients with EGFR-mutant NSCLC indicates a worse prognosis
por: Ouyang, Wen, et al.
Publicado: (2020)

Identification of the ferroptosis-related long non-coding RNAs signature to improve the prognosis prediction and immunotherapy response in patients with NSCLC
por: Li, Meng, et al.
Publicado: (2021)

SIRT1 Expression Is Associated with the Chemotherapy Response and Prognosis of Patients with Advanced NSCLC
por: Zhang, Tao, et al.
Publicado: (2013)

Long noncoding RNA AFAP1-AS1 is upregulated in NSCLC and associated with lymph node metastasis and poor prognosis
por: Leng, Xuechun, et al.
Publicado: (2018)

Poor prognosis of intra‐tumoural TRBV6‐6 variants in EGFR‐mutant NSCLC: Results from the ADJUVANT‐CTONG1104 trial
por: Chen, Cunte, et al.
Publicado: (2022)

Impact of the immune molecular profile of the tumor microenvironment on the prognosis of NSCLC
por: Ying, Hangjie, et al.
Publicado: (2023)

Competitive evolution of NSCLC tumor clones and the drug resistance mechanism of first-generation EGFR-TKIs in Chinese NSCLC patients
por: Deng, Qinfang, et al.
Publicado: (2018)

Lung microbiome alterations in NSCLC patients
por: Zheng, Leliang, et al.
Publicado: (2021)

A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC
por: Carmichael, Juliet A., et al.
Publicado: (2018)

EGFR amplification is a putative resistance mechanism for NSCLC–LM patients with TKI therapy and is associated with poor outcome
por: Yang, Hainan, et al.
Publicado: (2022)

High expression of CIP2A protein is associated with tumor aggressiveness in stage I–III NSCLC and correlates with poor prognosis
por: Cha, Geqi, et al.
Publicado: (2017)

Specific inhibitor of Notch-3 enhances the sensitivity of NSCLC cells to gemcitabine
por: Hu, Bi-Dan, et al.
Publicado: (2018)

Focus on Nivolumab in NSCLC
por: Cortinovis, Diego L., et al.
Publicado: (2016)

Angiogenesis Inhibitors in NSCLC
por: Manzo, Anna, et al.
Publicado: (2017)

Immunotherapeutic Advances for NSCLC
por: Massafra, Marco, et al.
Publicado: (2021)

Targeting AXL in NSCLC
por: Zaman, Aubhishek, et al.
Publicado: (2021)

Precision Surgery in NSCLC
por: Cannone, Giorgio, et al.
Publicado: (2023)

Clinical Significance of miR-183-3p and miR-182-5p in NSCLC and Their Correlation
por: Zhang, Tianxiang, et al.
Publicado: (2021)

The expression landscape of JAK1 and its potential as a biomarker for prognosis and immune infiltrates in NSCLC
por: Shen, Kaikai, et al.
Publicado: (2021)

Helicase-like transcription factor expression is associated with a poor prognosis in Non-Small-Cell Lung Cancer (NSCLC)
por: Dhont, Ludovic, et al.
Publicado: (2018)

Establishing a detection method for CCNY: a potentially significant clinical investigative marker in NSCLC patients
por: Ma, Li, et al.
Publicado: (2019)

Contribution of upregulated dipeptidyl peptidase 9 (DPP9) in promoting tumoregenicity, metastasis and the prediction of poor prognosis in non‐small cell lung cancer (NSCLC)
por: Tang, Zhiyuan, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_2l2q1cd6vi4ddd3l5d98sb4gr8